GLP-1RA对心血管疾病作用的研究进展  

Research progress on the effect of GLP-1RA on cardiovascular diseases

作　　者：章菁仪 焦丽君 王欣燕[1] ZHANG Jing-yi;JIAO Li-jun;WANG Xin-yan(Department of Respiratory Medicine,Second Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,150081,China)

机构地区：[1]哈尔滨医科大学附属第二医院呼吸内科,黑龙江哈尔滨150081

出　　处：《心血管康复医学杂志》2024年第3期364-367,共4页Chinese Journal of Cardiovascular Rehabilitation Medicine

摘　　要：2型糖尿病(T2DM)与心血管疾病(CVD)的发病率升高相关。近年来,众多心血管结局试验(CVOT)证实了胰高血糖素样肽-1受体激动剂(GLP-1RA)具有明确的心血管获益。本文对现有的GLP-1RA进行概述,特别关注它们对心血管疾病危险因素的临床影响以及作用机制,为临床防治CVD提供理论依据,同时为合并CVD的T2DM患者甚至非糖尿病患者提供更多的治疗选择。Type 2 diabetes mellitus(T2DM)is associated with an increased incidence rate of cardiovascular disease(CVD).In recent years,numerous cardiovascular outcome trials(CVOT)have confirmed the definite cardiovascular benefits of glucagon-like peptide-1 receptor agonists(GLP-1RA).In this paper,the existing GLP-1RAs were summarized,with special attention to their clinical impact on cardiovascular disease risk factors and mechanism of action,so as to provide theoretical basis for clinical prevention and treatment of CVD,and provide more treatment options not only for T2DM patients complicated with CVD,but also for non-diabetic patients.

关 键 词：心血管疾病 糖尿病 2型 胰高血糖素样肽-1受体激动剂 

分 类 号：R54[医药卫生—心血管疾病]